James M. Frates, Director at Sage Therapeutics, Inc. (SAGE), sold 8,000 shares at $162.22 ($1.3M) on 2019-05-06, disclosed to the SEC on 2019-05-06.
Open-market sale of $1.3M SAGE by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| Filing → |
| AMLX | SELL | 2026-02-04 | $52K | — | Filing → |
| AMLX | SELL | 2026-01-08 | $37K | — | Filing → |
| AMLX | SELL | 2025-10-02 | $309K | — | Filing → |